Ibnsina Pharma (CAI:ISPH) Total Liabilities : E£19,108 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Ibnsina Pharma Total Liabilities?

Ibnsina Pharma's Total Liabilities for the quarter that ended in Mar. 2024 was E£19,108 Mil.

Ibnsina Pharma's quarterly Total Liabilities declined from Sep. 2023 (E£17,269.90 Mil) to Dec. 2023 (E£17,100.69 Mil) but then increased from Dec. 2023 (E£17,100.69 Mil) to Mar. 2024 (E£19,107.96 Mil).

Ibnsina Pharma's annual Total Liabilities increased from Dec. 2021 (E£11,284.46 Mil) to Dec. 2022 (E£11,603.92 Mil) and increased from Dec. 2022 (E£11,603.92 Mil) to Dec. 2023 (E£17,100.69 Mil).

Ibnsina Pharma Total Liabilities Historical Data

The historical data trend for Ibnsina Pharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ibnsina Pharma Total Liabilities Chart

Ibnsina Pharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

8,169.88

9,250.43

11,284.46

11,603.92

17,100.69

Ibnsina Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															15,323.15	14,986.10	17,269.90	17,100.69	19,107.96

Ibnsina Pharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Ibnsina Pharma's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	15924.257	+	(1176.434	+	-6.821210263297E-13
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	17,101

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	18549.811	-	1449.12
	=	17,101

Ibnsina Pharma's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	18254.159	+	(853.797	+	-1.3642420526594E-12
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	19,108

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	20655.087	-	1547.13
	=	19,108

Ibnsina Pharma Total Liabilities Related Terms

Thank you for viewing the detailed overview of Ibnsina Pharma's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Ibnsina Pharma (CAI:ISPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Ibnsina Pharma (CAI:ISPH) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Industrial zone 1, PO box 91, Obour, EGY

Website

http://www.ibnsina-pharma.com

Ibnsina Pharma is an Egypt based pharmaceutical distribution company. It is engaged in purchasing and selling in wholesale and distribution of pharmaceutical, semi- pharmaceutical and cosmetic products. It distributes a portfolio of pharmaceutical products from local and multinational pharmaceutical companies to retail pharmacies, wholesalers, hospitals, and public health institutions. In addition, the company also offers services including warehousing and logistics, marketing solutions, importation, and packaging, market research, and analysis.

Ibnsina Pharma (CAI:ISPH) Headlines

No Headlines